Korean J Urol Oncol.
2020 Aug;18(2):124-139. 10.22465/kjuo.2020.18.2.124.
Management of Patients With Advanced Prostate Cancer: Establishment ofTreatment Guidelines Through Prostate Cancer Summit (PCAS) 2016Composed of Korean Prostate Cancer Experts
- Jang CT1
- Kim HJ2
- Kim MK3
- Park SW4
- Park SC5
- Park JY6
- Lee DH7
- Lee SH8
- Jeon HG1
- Chung JH1
- Jeong H9
- Jo MK10
- Hong SH11
- Kwak C12
- Lee JY11
- Kwon DD13
- Kim CS14
- Jeon SS
1
- Affiliations
-
- 1Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 2Department of Urology, Konyang University College of Medicine, Daejeon, Korea
- 3Department of Urology, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea
- 4Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea
- 5Department of Urology, Wonkwang University Hospital, Iksan, Korea
- 6Department of Urology, Korea University College of Medicine, Seoul, Korea
- 7Department of Urology, Ewha Womans University College of Medicine, Seoul, Korea
- 8Department of Urology, Yonsei University College of Medicine, Seoul, Korea
- 9Department of Urology, Seoul Metropolitan Government, Seoul National University Boramae Medical Center, Seoul, Korea
- 10Department of Urology, Korea Cancer Centre Hospital, Seoul, Korea
- 11Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 12Department of Urology, Seoul National University Hospital, Seoul National University School of Medicine, Seoul, Korea
- 13Department of Urology, Chonnam National University Medical School, Gwangju, Korea
- 14Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- KMID: 2505893
- DOI: http://doi.org/10.22465/kjuo.2020.18.2.124
Abstract
- Purpose
The Advanced Prostate Cancer Consensus Conference (APCCC) 2015 was based on topics withcontroversy in the field of advanced prostate cancer. To understand the Korean urologists perspective regardingthe issues, we have conducted a questionnaire named Prostate Cancer Summit (PCAS) 2016, with 9 importantsubtopics.
Materials and Methods
Total 9 subtopics have been decided and questions were developed regarding eachsubtopic. The questions were based on that of APCCC 2015 and translated into Korean for better understanding.Total 51 panelists have voted online on 85 different questions.
Results
The survey concluded that testosterone should be measured as a diagnostic criterion for castrationresistance prostate cancer (CRPC) and that consensus was reached on issues such as the use of androgenreceptor pathway inhibitors in the treatment of predocetaxel and postdocetaxel in CRPC patients. In addition,76% of the participants agreed that imaging tests were needed before new treatment in CRPC patients, anda majority of participants agreed that periodic imaging tests are necessary regardless of symptoms during treatmentfor CRPC. However, some issues, such as the use of prostate-specific antigen-based triggers for remediationin CRPC patients, the endocrine manipulation in nonmetastatic CRPC patients, and the onset of treatment inasymptomatic metastatic CRPC patients, were not agreed.
Conclusions
The results from PCAS 2016 has addressed some of the issues with controversy. Although thevoting results are subjective, it will help guide treatment decisions in topics with less evidence.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Prostate Cancer in Young Man
- Chemoprevention
- Expert Group Consensus Opinion on Prostate Cancer Diagnosis and Management in India: Part 1 of 2
- Prostate Biopsy: General Consideration and Systematic Biopsy
- The Diagnostic Value of Prostate-specific Antigen and the of Routine Laboratory Examination for Early Detection
